GLP-1 receptor agonist use in adults with concurrent type 2 diabetes and obesity was associated with increased risk for osteoporosis, gout and osteomalacia vs. a matched control group, according to ...

A common medicine used to treat weak bones may also help protect the brain, according to a new large study from researchers at the University of Hong Kong. The study suggests that a group of drugs ...

A research team from the Department of Pharmacology and Pharmacy, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has found that nitrogen-containing bisphosphonates (NBPs), a ...

The GPR133 receptor is expressed by osteoblasts, the cells that make bone. The study suggests that this receptor helps those cells sense two kinds of input: mechanical strain and signals relayed by ...

A pattern of musculoskeletal injuries spurred researchers to conduct a study on whether using the popular weight-loss and diabetes drugs increased a person’s risk of other health conditions.

Some people can take “drug holidays” for years, sometimes, to keep the bone from becoming “frozen” and brittle.

Patients with glucocorticoid-induced osteoporosis on romosozumab show greater gains in lumbar spine bone mineral density than those on denosumab and comparable gains with those on teriparatide.

Explore updates on potential GLP-1 uses and risks, including addiction treatment, bone injury concerns, and kidney disease effectiveness.

GLP-1 drugs, such as Ozempic and Wegovy, may slightly increase the risk of osteoporosis, gout, and the rare metabolic bone disease osteomalacia, a recent study suggests.

At age 48, I underwent a lumpectomy, chemo and radiation for stage I breast cancer. All is good so far, but I started ...

For the osteoporosis in my hip, I took alendronate for five years, but it did not stop the bone loss. I am now on Prolia, which has helped. I am healthy and fairly active. How lon ...